Cargando…

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer

Triple‐negative breast cancer (TNBC) has a relatively poor outcome. Acquired chemoresistance is a major clinical challenge for TNBC patients. Previously, we reported that kinase‐dead Aurora kinase A (Aurora‐A) could effectively transactivate the FOXM1 promoter. Here, we demonstrate an additional pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Na, Wang, Chang, Wang, Jian, Wang, Zifeng, Huang, Di, Yan, Min, Kamran, Muhammad, Liu, Quentin, Xu, BangLao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714217/ https://www.ncbi.nlm.nih.gov/pubmed/31359594 http://dx.doi.org/10.1111/jcmm.14538

Ejemplares similares

Activation of Aurora A kinase increases YAP stability via blockage of autophagy
por: Wang, Peng, et al.
Publicado: (2019)

Identification of FOXM1 as a specific marker for triple-negative breast cancer
por: Tan, Yanli, et al.
Publicado: (2018)

Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma
por: Su, Wen-Lung, et al.
Publicado: (2020)

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells
por: Scharer, Christopher D, et al.
Publicado: (2008)

Role of aurora kinase B in regulating resistance to paclitaxel in breast cancer cells
por: Liu, Min, et al.
Publicado: (2022)

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer
por: Skov, Natascha, et al.
Publicado: (2022)

Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity
por: Zhang, Yue, et al.
Publicado: (2018)

Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition
por: Zhang, Zijian, et al.
Publicado: (2021)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
por: Jalalirad, Mohammad, et al.
Publicado: (2021)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019)

FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells
por: Yang, N, et al.
Publicado: (2017)

CEP55 promotes cilia disassembly through stabilizing Aurora A kinase
por: Zhang, Yu-Cheng, et al.
Publicado: (2021)

Nuclear Aurora kinase A triggers programmed death‐ligand 1‐mediated immune suppression by activating MYC transcription in triple‐negative breast cancer
por: Sun, Shulan, et al.
Publicado: (2021)

Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast Cancer
por: Xu, Jie, et al.
Publicado: (2013)

Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family
por: Kawai, Masaaki, et al.
Publicado: (2015)

Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer
por: Dey, Parama, et al.
Publicado: (2020)

The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
por: Ulhaka, Karan, et al.
Publicado: (2021)

Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis
por: Kamran, M, et al.
Publicado: (2017)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)

Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance
por: Khongkow, P, et al.
Publicado: (2016)

Equatorial aurora: the aurora-like airglow in the negative magnetic anomaly
por: He, Fei, et al.
Publicado: (2020)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2018)

FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells
por: Hamurcu, Zuhal, et al.
Publicado: (2016)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020)

Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle
por: Hochegger, Helfrid, et al.
Publicado: (2013)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Li, Yu, et al.
Publicado: (2021)

Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2019)

The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
por: Hou, Youxiang, et al.
Publicado: (2017)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
por: Hartsink-Segers, S A, et al.
Publicado: (2013)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
por: Diamond, Jennifer R., et al.
Publicado: (2018)

Aurora kinase A suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells
por: Xu, Ling-Zhi, et al.
Publicado: (2014)

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
por: Gully, Christopher P, et al.
Publicado: (2010)

The Aurora Kinases in Cell Cycle and Leukemia
por: Goldenson, Benjamin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vin5f21qhvu7c7p06rntq3f6me